U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2023
446
Substance Class Protein
Created
by admin
on Tue Apr 01 20:55:03 GMT 2025
Edited
by admin
on Tue Apr 01 20:55:03 GMT 2025
Protein Type BISPECIFIC ANTIBODY
Protein Sub Type IGG2
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
L0HR9A577V
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
PF-06863135
Preferred Name English
Elranatamab
INN   USAN  
Official Name English
elranatamab [INN]
Common Name English
ANTI-CD3/ANTI-BCMA BISPECIFIC MONOCLONAL ANTIBODY PF-06863135
Common Name English
RN613
Code English
ELRANATAMAB [USAN]
Common Name English
RN-613
Code English
Elranatamab [WHO-DD]
Common Name English
Immunoglobulin G2-kappa, anti-(Homo sapiens T-cell surface glycoprotein CD3 epsilon chain CD3E (T-cell surface antigen T3/Leu-4 epsilon chain)), human-Mus musculus monoclonal disulfide with immunoglobulin G2-kappa, anti-(Homo sapiens - Tumor necrosis fac
Common Name English
Immunoglobulin G2 [224-arginine,265-alanine,330-serine,331-serine], anti-(human CD3 antigen ?-chain) (human-Mus musculus monoclonal PF-06863059 ?2-chain), disulfide with human-Mus musculus monoclonal PF-06863059 ?-chain, (223?217?)(227?221?)(230?224?)-tr
Common Name English
B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 840721
Created by admin on Tue Apr 01 20:55:03 GMT 2025 , Edited by admin on Tue Apr 01 20:55:03 GMT 2025
Code System Code Type Description
DAILYMED
L0HR9A577V
Created by admin on Tue Apr 01 20:55:03 GMT 2025 , Edited by admin on Tue Apr 01 20:55:03 GMT 2025
PRIMARY
USAN
HI-199
Created by admin on Tue Apr 01 20:55:03 GMT 2025 , Edited by admin on Tue Apr 01 20:55:03 GMT 2025
PRIMARY
FDA UNII
L0HR9A577V
Created by admin on Tue Apr 01 20:55:03 GMT 2025 , Edited by admin on Tue Apr 01 20:55:03 GMT 2025
PRIMARY
CAS
2408850-14-4
Created by admin on Tue Apr 01 20:55:03 GMT 2025 , Edited by admin on Tue Apr 01 20:55:03 GMT 2025
PRIMARY
SMS_ID
300000011763
Created by admin on Tue Apr 01 20:55:03 GMT 2025 , Edited by admin on Tue Apr 01 20:55:03 GMT 2025
PRIMARY
NCI_THESAURUS
C146860
Created by admin on Tue Apr 01 20:55:03 GMT 2025 , Edited by admin on Tue Apr 01 20:55:03 GMT 2025
PRIMARY
INN
11838
Created by admin on Tue Apr 01 20:55:03 GMT 2025 , Edited by admin on Tue Apr 01 20:55:03 GMT 2025
PRIMARY
DRUG BANK
DB15395
Created by admin on Tue Apr 01 20:55:03 GMT 2025 , Edited by admin on Tue Apr 01 20:55:03 GMT 2025
PRIMARY
From To
1_22 1_98
1_135 3_219
1_148 1_204
1_223 2_217
1_227 2_221
1_230 2_224
1_261 1_321
1_367 1_425
2_22 2_96
2_129 4_215
2_142 2_198
2_255 2_315
2_361 2_419
3_23 3_94
3_139 3_199
4_23 4_89
4_135 4_195
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_297
N 2_291
Related Record Type Details
CD3
CD3
TARGET -> ACTIVATOR
Elranatamab-BCMM
SUB_CONCEPT->SUBSTANCE
TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 17
TARGET->ANTIGEN
Related Record Type Details
Elranatamab
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966